Skip to main content
Erschienen in: Drugs 5/2005

01.04.2005 | Review Article

Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

verfasst von: Dr Michael T. Nurmohamed, Ben A. C. Dijkmans

Erschienen in: Drugs | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Over the last decade, several new drugs have become available for the treatment of patients with rheumatoid arthritis. These agents include the new disease-modifying antirheumatic drug (DMARD) leflunomide and the biologic agents, tumor necrosis factor (TNF)-α antagonists and an interleukin (IL)-1 receptor antagonist.
Methotrexate is commonly used as the first DMARD, has a well documented clinical efficacy and slows radiological deterioration. Sulfasalazine appears to have similar properties, albeit to a lesser extent. Leflunomide has similar efficacy as methotrexate but it is less tolerated than sulfasalazine. The adverse effect profiles of these three drugs makes regular laboratory monitoring mandatory.
Several combination therapies with DMARDs were proven to be more effective than mono-DMARD therapy. However, until now these strategies have not been widely adopted.
TNF antagonists are potent anti-inflammatory drugs, with a rapid onset of effects compared with traditional DMARDs. The IL-1 receptor antagonist, anakinra, has an intermediate place between methotrexate and the TNF antagonists with respect to efficacy.
The adverse effects of TNF antagonists include an increased incidence of common and opportunistic infections. Thus far, anakinra has not been associated with an enhanced rate of opportunistic infections.
Some of the biologic agents have been associated with worsening heart failure and demyelinating disease. The limited long-term safety data of the biologic agents are a point of concern because, at present, an enhanced risk for malignancies, particularly lymphoma, can not be excluded.
Drug costs of traditional DMARDs are up to $US3000 per year, whereas for the biologics the yearly drug costs range between $US16 000 and >$US20 000. Cost-effectiveness analyses are necessary to determine whether or not these high costs are justified. Unfortunately, adequate, prospective, economic evaluations are not yet available. Until these become available, treatment decisions will be based on the balance of direct costs and indirect costs and expected cost savings in the future.
Literatur
1.
Zurück zum Zitat Lems WF, Dijkmans BAC. Rheumatoid arthritis: clinical aspects and its variants. In: Firestein GS, Panayi GS, Wollheim FA, editors. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. New York: Oxford University Press 2000: 213–25 Lems WF, Dijkmans BAC. Rheumatoid arthritis: clinical aspects and its variants. In: Firestein GS, Panayi GS, Wollheim FA, editors. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. New York: Oxford University Press 2000: 213–25
2.
Zurück zum Zitat American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328–46CrossRef American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328–46CrossRef
3.
Zurück zum Zitat Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209–18PubMedCrossRef Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209–18PubMedCrossRef
4.
Zurück zum Zitat Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000; 39: 28–33CrossRef Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000; 39: 28–33CrossRef
5.
Zurück zum Zitat American College of Rheumatology ad hoc Committees on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713–22CrossRef American College of Rheumatology ad hoc Committees on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713–22CrossRef
6.
Zurück zum Zitat Fries JF. Current treatment paradigms in rheumatoid arthritis. Rheumatology 2000; 39 Suppl. 1: 30–5PubMedCrossRef Fries JF. Current treatment paradigms in rheumatoid arthritis. Rheumatology 2000; 39 Suppl. 1: 30–5PubMedCrossRef
7.
Zurück zum Zitat Rau R. Methotrexate. In: Firestein GS, Panayi GS, Wollheim FA, editors. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. Oxford (NY): Oxford University Press, 2000: 337–50 Rau R. Methotrexate. In: Firestein GS, Panayi GS, Wollheim FA, editors. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. Oxford (NY): Oxford University Press, 2000: 337–50
8.
Zurück zum Zitat Aletahaq D, Stamm T, Kapral T, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003; 62: 944–51CrossRef Aletahaq D, Stamm T, Kapral T, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003; 62: 944–51CrossRef
9.
Zurück zum Zitat Capell H, Madhok R. Disease-modifying antirheumatic drugs, 2: sulfasalazine and dapson. In: Huchberg MC, Silman AD, Smollen JS, et al., editors. Rheumatoloy. Edinburgh: Mosby, 2003: 405–16 Capell H, Madhok R. Disease-modifying antirheumatic drugs, 2: sulfasalazine and dapson. In: Huchberg MC, Silman AD, Smollen JS, et al., editors. Rheumatoloy. Edinburgh: Mosby, 2003: 405–16
10.
Zurück zum Zitat Boers M. Rheumatoid arthritis: treatment of early disease. Rheum Dis Clin North Am 2001; 27: 405–14PubMedCrossRef Boers M. Rheumatoid arthritis: treatment of early disease. Rheum Dis Clin North Am 2001; 27: 405–14PubMedCrossRef
11.
Zurück zum Zitat Cush JJ. Cytokine therapies. In: Huchberg MC, Silman AD, Smollen JS, et al., editors. Rheumatoloy. Edinburgh: Mosby, 2003: 405–16 Cush JJ. Cytokine therapies. In: Huchberg MC, Silman AD, Smollen JS, et al., editors. Rheumatoloy. Edinburgh: Mosby, 2003: 405–16
12.
Zurück zum Zitat Nurmohamed MT, van Halm V, Dijkmans BAC. Cardiovascular risk profile of antirheumatic agents in patients with osteoar-thritis and rheumatoid arthritis. Drugs 2002; 62(11): 1599–609PubMedCrossRef Nurmohamed MT, van Halm V, Dijkmans BAC. Cardiovascular risk profile of antirheumatic agents in patients with osteoar-thritis and rheumatoid arthritis. Drugs 2002; 62(11): 1599–609PubMedCrossRef
13.
Zurück zum Zitat Kirwan JR. Systemic low-dose glucocorticoid in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 389–403PubMedCrossRef Kirwan JR. Systemic low-dose glucocorticoid in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 389–403PubMedCrossRef
14.
Zurück zum Zitat Telia MN, Feinglass J, Chang RW. Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001–2002. Curr Opin Rheumatol 2003; 15: 127–31CrossRef Telia MN, Feinglass J, Chang RW. Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001–2002. Curr Opin Rheumatol 2003; 15: 127–31CrossRef
15.
Zurück zum Zitat Bakker CH, Rutten-van Molken MPMH, van Doorslaar EK, et al. Health related utility assessment by rating scale and standard gamble in patients with ankylosing spondylitis or fibromyalgia. Patient Educ Couns 1993; 20: 145–52PubMedCrossRef Bakker CH, Rutten-van Molken MPMH, van Doorslaar EK, et al. Health related utility assessment by rating scale and standard gamble in patients with ankylosing spondylitis or fibromyalgia. Patient Educ Couns 1993; 20: 145–52PubMedCrossRef
16.
Zurück zum Zitat Cronstein BN, Eberle MA, Gruber HE, et al. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991; 88: 2441–5PubMedCrossRef Cronstein BN, Eberle MA, Gruber HE, et al. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991; 88: 2441–5PubMedCrossRef
17.
Zurück zum Zitat Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675–82PubMedCrossRef Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675–82PubMedCrossRef
18.
Zurück zum Zitat Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86–90PubMedCrossRef Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86–90PubMedCrossRef
19.
Zurück zum Zitat van Ede AE, Laan RFJM, Rood MJ, et al. Effect of folic or folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: a double blind randomised placebo-controlled multi-centre 48-week study. Arthritis Rheum 2001; 44: 1515–24PubMedCrossRef van Ede AE, Laan RFJM, Rood MJ, et al. Effect of folic or folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: a double blind randomised placebo-controlled multi-centre 48-week study. Arthritis Rheum 2001; 44: 1515–24PubMedCrossRef
20.
Zurück zum Zitat Willkens RF, Watson MA, Paxson CS. Low-dose pulse methotrexate in rheumatoid arthritis. J Rheumatol 1980; 7: 501–5PubMed Willkens RF, Watson MA, Paxson CS. Low-dose pulse methotrexate in rheumatoid arthritis. J Rheumatol 1980; 7: 501–5PubMed
21.
Zurück zum Zitat Wilke WS, Calabrese LH, Scherbel AL. Methotrexate in the treatment of rheumatoid arthritis: pilot study. Cleve Clin Q 1980; 47: 305–9PubMed Wilke WS, Calabrese LH, Scherbel AL. Methotrexate in the treatment of rheumatoid arthritis: pilot study. Cleve Clin Q 1980; 47: 305–9PubMed
22.
Zurück zum Zitat Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75: 69–73PubMedCrossRef Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75: 69–73PubMedCrossRef
23.
Zurück zum Zitat Anderson PA, Wets SG, O’Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Ann Intern Med 1985; 103: 489–96 Anderson PA, Wets SG, O’Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Ann Intern Med 1985; 103: 489–96
24.
Zurück zum Zitat Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11: 760–2PubMed Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11: 760–2PubMed
25.
Zurück zum Zitat Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818–22PubMedCrossRef Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818–22PubMedCrossRef
26.
Zurück zum Zitat Williams HJ, Willkens RF, Samuelson CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985; 28: 721–9PubMedCrossRef Williams HJ, Willkens RF, Samuelson CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985; 28: 721–9PubMedCrossRef
27.
Zurück zum Zitat Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987; 107: 358–66PubMed Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987; 107: 358–66PubMed
28.
Zurück zum Zitat Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885–94 Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885–94
29.
Zurück zum Zitat Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309–18PubMedCrossRef Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309–18PubMedCrossRef
30.
Zurück zum Zitat O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydrox-ychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287–91PubMedCrossRef O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydrox-ychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287–91PubMedCrossRef
31.
Zurück zum Zitat Haagsma U, van Riel PLCM, De Jong AJL, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomised, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082–8PubMedCrossRef Haagsma U, van Riel PLCM, De Jong AJL, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomised, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082–8PubMedCrossRef
32.
Zurück zum Zitat Karger T, Rau R. Treatment of chronic polyarthritis with low-dose methotrexate [in German]. Dtsch Med Wochenschr 1988 May 27; 113(21): 839–46PubMedCrossRef Karger T, Rau R. Treatment of chronic polyarthritis with low-dose methotrexate [in German]. Dtsch Med Wochenschr 1988 May 27; 113(21): 839–46PubMedCrossRef
33.
Zurück zum Zitat Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999; 353: 1568–73PubMedCrossRef Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999; 353: 1568–73PubMedCrossRef
34.
Zurück zum Zitat Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 138–45PubMedCrossRef Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 138–45PubMedCrossRef
35.
Zurück zum Zitat Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20: 639–44PubMed Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20: 639–44PubMed
36.
Zurück zum Zitat Weinblatt ME, Trentham DE, Fraser PA. Longterm prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 167–75PubMedCrossRef Weinblatt ME, Trentham DE, Fraser PA. Longterm prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 167–75PubMedCrossRef
37.
Zurück zum Zitat Alarcon GS, Tracy IC, Blackburn Jr WD. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32: 671–6PubMedCrossRef Alarcon GS, Tracy IC, Blackburn Jr WD. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32: 671–6PubMedCrossRef
38.
Zurück zum Zitat Rau R, Schleusser B, Herborn G, et al. Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997; 24: 1881–9PubMed Rau R, Schleusser B, Herborn G, et al. Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997; 24: 1881–9PubMed
39.
Zurück zum Zitat Kremer JM, Lee JK. A long-term prospective study of the use of I: methotrexate in rheumatoid arthritis: update after a mean of fifty-three months. Arthritis Rheum 1988; 31: 477–584 Kremer JM, Lee JK. A long-term prospective study of the use of I: methotrexate in rheumatoid arthritis: update after a mean of fifty-three months. Arthritis Rheum 1988; 31: 477–584
40.
Zurück zum Zitat Gutierrez-Urena S, Molina JF, Garcia CO, et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 272–6PubMedCrossRef Gutierrez-Urena S, Molina JF, Garcia CO, et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 272–6PubMedCrossRef
41.
Zurück zum Zitat Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986; 13: 440–1PubMed Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986; 13: 440–1PubMed
42.
Zurück zum Zitat Tanaka Y, Shiozawa K, Nishibayashi Y, et al. Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy? J Rheumatol 1992; 19: 1320–1PubMed Tanaka Y, Shiozawa K, Nishibayashi Y, et al. Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy? J Rheumatol 1992; 19: 1320–1PubMed
43.
44.
Zurück zum Zitat Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low-dose pulse methotrexate. Semin Arthritis Rheum 1987; 16: 186–95PubMedCrossRef Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low-dose pulse methotrexate. Semin Arthritis Rheum 1987; 16: 186–95PubMedCrossRef
45.
Zurück zum Zitat Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985; 12 Suppl. 12: 35–9 Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985; 12 Suppl. 12: 35–9
46.
Zurück zum Zitat Phillips C, Cera PJ, Mangan TF, et al. Clinical liver disease in rheumatoid arthritis patients on methotrexate. J Rheumatol 1992; 19: 229–33PubMed Phillips C, Cera PJ, Mangan TF, et al. Clinical liver disease in rheumatoid arthritis patients on methotrexate. J Rheumatol 1992; 19: 229–33PubMed
47.
Zurück zum Zitat Rau R. Toxicity of methotrexate in rheumatoid arthritis. In: Weinblatt ME, editor. A comprehensive guide to new therapeutic approaches of methotrexate in rheumatoid arthritis. Chicago (IL): Pharma Libri, 1987: 63–77 Rau R. Toxicity of methotrexate in rheumatoid arthritis. In: Weinblatt ME, editor. A comprehensive guide to new therapeutic approaches of methotrexate in rheumatoid arthritis. Chicago (IL): Pharma Libri, 1987: 63–77
48.
Zurück zum Zitat Kremer JM, Alarcón GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316–28PubMedCrossRef Kremer JM, Alarcón GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316–28PubMedCrossRef
49.
Zurück zum Zitat Scideman P, Muller-Suur R, Ekman E. Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993; 20: 1126–8 Scideman P, Muller-Suur R, Ekman E. Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993; 20: 1126–8
50.
Zurück zum Zitat Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22: 38–40PubMed Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22: 38–40PubMed
51.
Zurück zum Zitat Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40: 971–3PubMedCrossRef Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40: 971–3PubMedCrossRef
52.
Zurück zum Zitat Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 148–58PubMedCrossRef Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 148–58PubMedCrossRef
53.
Zurück zum Zitat Starkebaum G. Rheumatoid arthritis, methotrexate, and lymphama: risk substitution, or cat and mouse with Epstein-Barr virus. J Rheumatol 2001; 28: 2573–5PubMed Starkebaum G. Rheumatoid arthritis, methotrexate, and lymphama: risk substitution, or cat and mouse with Epstein-Barr virus. J Rheumatol 2001; 28: 2573–5PubMed
54.
Zurück zum Zitat Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphoma’s in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909–15PubMedCrossRef Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphoma’s in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909–15PubMedCrossRef
55.
Zurück zum Zitat Georgescu L, Quinn GC, Schwartzman S, et al. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997; 26: 794–04PubMedCrossRef Georgescu L, Quinn GC, Schwartzman S, et al. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997; 26: 794–04PubMedCrossRef
56.
Zurück zum Zitat Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14: 1943–9PubMed Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14: 1943–9PubMed
57.
Zurück zum Zitat Moder KG, Tefferi A, Cohen MD, et al. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995; 99: 276–81PubMedCrossRef Moder KG, Tefferi A, Cohen MD, et al. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995; 99: 276–81PubMedCrossRef
58.
Zurück zum Zitat Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in treatment of rheumatoid arthritis. Drugs 1995; 50: 137–56PubMedCrossRef Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in treatment of rheumatoid arthritis. Drugs 1995; 50: 137–56PubMedCrossRef
59.
Zurück zum Zitat Schroder H, Campbell D. Absorption, metabolism and excretion of salicylazo-sulfapyridine in man. Clin Pharmacol Ther 1972; 13: 539–51PubMed Schroder H, Campbell D. Absorption, metabolism and excretion of salicylazo-sulfapyridine in man. Clin Pharmacol Ther 1972; 13: 539–51PubMed
60.
Zurück zum Zitat Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis. BMJ 1985; 290: 1535–8PubMedCrossRef Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis. BMJ 1985; 290: 1535–8PubMedCrossRef
61.
Zurück zum Zitat Porter DR, Capell HA. The use of sulfasalzine as a disease modifyinig antirheumatic drug. Baillieres Clin Rheumatol 1990; 4: 535–51PubMedCrossRef Porter DR, Capell HA. The use of sulfasalzine as a disease modifyinig antirheumatic drug. Baillieres Clin Rheumatol 1990; 4: 535–51PubMedCrossRef
62.
Zurück zum Zitat Bird HA. Sulphasalzine, sulfapyridine or 5-aminosalicylic acid-which is the active moiety in rheumatoid arthitis. Br J Rheumatol 1995; 35 Suppl. 2: 16–9 Bird HA. Sulphasalzine, sulfapyridine or 5-aminosalicylic acid-which is the active moiety in rheumatoid arthitis. Br J Rheumatol 1995; 35 Suppl. 2: 16–9
63.
Zurück zum Zitat Pullar T, Hunter JA, Capell HA. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis 1987; 46: 398–402PubMedCrossRef Pullar T, Hunter JA, Capell HA. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis 1987; 46: 398–402PubMedCrossRef
64.
Zurück zum Zitat Van der Heijde DM, van Riel PLCM, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; I: 1036–8CrossRef Van der Heijde DM, van Riel PLCM, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; I: 1036–8CrossRef
65.
Zurück zum Zitat Van der Heijde DM, van Riel PLCM, Nuver-Zwart IH, et al. Alternative methods for analysis of radiographic damage in a randomized, double-blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine. J Rheumatol 2000; 27: 535–8PubMed Van der Heijde DM, van Riel PLCM, Nuver-Zwart IH, et al. Alternative methods for analysis of radiographic damage in a randomized, double-blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine. J Rheumatol 2000; 27: 535–8PubMed
66.
Zurück zum Zitat Wolfe F, Cush JJ, O’Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001 Jun; 28(6): 1423–30PubMed Wolfe F, Cush JJ, O’Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001 Jun; 28(6): 1423–30PubMed
67.
Zurück zum Zitat Maetzel A, Wond A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 2000; 39: 975–81PubMedCrossRef Maetzel A, Wond A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 2000; 39: 975–81PubMedCrossRef
68.
Zurück zum Zitat Amos R, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. BMJ (Clin Res Ed) 1986; 293: 420–3CrossRef Amos R, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. BMJ (Clin Res Ed) 1986; 293: 420–3CrossRef
69.
Zurück zum Zitat Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988; 31: 702–13PubMedCrossRef Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988; 31: 702–13PubMedCrossRef
70.
Zurück zum Zitat Donvan S, Hawley S, MacCarthy J, et al. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a cooperating clinics study. Br J Rheumatol 1990; 29: 201–4CrossRef Donvan S, Hawley S, MacCarthy J, et al. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a cooperating clinics study. Br J Rheumatol 1990; 29: 201–4CrossRef
71.
Zurück zum Zitat Nurmohamed MT, Soesan M, van Oers MHJ, et al. Cyclosporin for sulfasalazine-induced aplastic anaemia in a patient with rheumatoid arthritis. Rheumatology 2000; 39: 1431–3PubMedCrossRef Nurmohamed MT, Soesan M, van Oers MHJ, et al. Cyclosporin for sulfasalazine-induced aplastic anaemia in a patient with rheumatoid arthritis. Rheumatology 2000; 39: 1431–3PubMedCrossRef
72.
Zurück zum Zitat Mogadam M, Dobbins 3rd WO, Korelitz BI, et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corti-costeroids on fetal outcome. Gastroenterology 1981 Jan; 80(1): 72–6PubMed Mogadam M, Dobbins 3rd WO, Korelitz BI, et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corti-costeroids on fetal outcome. Gastroenterology 1981 Jan; 80(1): 72–6PubMed
73.
Zurück zum Zitat Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77-1726: inhibition of pyrimidine nucleotide synthesis and protein tyro-sine phosphorylation. Biochem Pharmacol 1996; 52: 527–34PubMedCrossRef Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77-1726: inhibition of pyrimidine nucleotide synthesis and protein tyro-sine phosphorylation. Biochem Pharmacol 1996; 52: 527–34PubMedCrossRef
74.
Zurück zum Zitat Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159: 22–7PubMed Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159: 22–7PubMed
75.
Zurück zum Zitat Ruckemann K, Fairbanks LD, Carrey EA, et al. A. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998; 273: 21682–91 Ruckemann K, Fairbanks LD, Carrey EA, et al. A. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998; 273: 21682–91
76.
Zurück zum Zitat Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993; 334: 161–4PubMedCrossRef Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993; 334: 161–4PubMedCrossRef
77.
Zurück zum Zitat Xu XL, Williams JW, Bremer EG, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270: 12398–403PubMedCrossRef Xu XL, Williams JW, Bremer EG, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270: 12398–403PubMedCrossRef
78.
Zurück zum Zitat Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160: 1581–8PubMed Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160: 1581–8PubMed
79.
Zurück zum Zitat Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J Immunol 1999; 162: 2095–102PubMed Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J Immunol 1999; 162: 2095–102PubMed
80.
Zurück zum Zitat Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43: 1820–30PubMedCrossRef Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43: 1820–30PubMedCrossRef
81.
Zurück zum Zitat Kraan MC, de Koster BM, Elferink JG, et al. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43: 1488–95PubMedCrossRef Kraan MC, de Koster BM, Elferink JG, et al. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43: 1488–95PubMedCrossRef
82.
Zurück zum Zitat Schrand LM, Tuetken R. Rheumatoid arthritis: update on the newest DMARDs and their potential place in therapy. Formulary 2002 Jun 1;37: 301–11 Schrand LM, Tuetken R. Rheumatoid arthritis: update on the newest DMARDs and their potential place in therapy. Formulary 2002 Jun 1;37: 301–11
83.
Zurück zum Zitat Osiri M, Shea B, Suarez Almazor M, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30: 1182–90PubMed Osiri M, Shea B, Suarez Almazor M, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30: 1182–90PubMed
84.
Zurück zum Zitat Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995; 38: 1595–603PubMedCrossRef Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995; 38: 1595–603PubMedCrossRef
85.
Zurück zum Zitat Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542–50PubMedCrossRef Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542–50PubMedCrossRef
86.
Zurück zum Zitat Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259–66PubMedCrossRef Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259–66PubMedCrossRef
87.
Zurück zum Zitat Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655–65PubMedCrossRef Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655–65PubMedCrossRef
88.
Zurück zum Zitat Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984–92PubMedCrossRef Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984–92PubMedCrossRef
89.
Zurück zum Zitat Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow-up of a double blind placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 913–23PubMedCrossRef Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow-up of a double blind placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 913–23PubMedCrossRef
90.
Zurück zum Zitat Weinblatt MW, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety and efficacy of combination treatmetn with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322–8PubMedCrossRef Weinblatt MW, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety and efficacy of combination treatmetn with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322–8PubMedCrossRef
91.
Zurück zum Zitat Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 2002; 137: 726–33PubMed Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 2002; 137: 726–33PubMed
92.
Zurück zum Zitat Hewitson PJ, Debroe S, McBride A, et al. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J Clin Pharm Ther 2000; 25: 295–302PubMedCrossRef Hewitson PJ, Debroe S, McBride A, et al. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J Clin Pharm Ther 2000; 25: 295–302PubMedCrossRef
93.
Zurück zum Zitat Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35
94.
Zurück zum Zitat van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl 2004 Jun; 71: 21–4PubMed van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl 2004 Jun; 71: 21–4PubMed
95.
Zurück zum Zitat Smolen JS, Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology 2000; 39 Suppl. 1: 48–56PubMedCrossRef Smolen JS, Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology 2000; 39 Suppl. 1: 48–56PubMedCrossRef
96.
Zurück zum Zitat Van Pelt A, van Schaardenburg DJ, Bultink IEM, et al. High discontinuation rate of treatment with leflunomide in daily practice [abstract]. Arthritis Rheum 2001; 44 Suppl.: S143 Van Pelt A, van Schaardenburg DJ, Bultink IEM, et al. High discontinuation rate of treatment with leflunomide in daily practice [abstract]. Arthritis Rheum 2001; 44 Suppl.: S143
97.
Zurück zum Zitat Van Halm VP, Nurmohamed MT, van Schaardenburg D, et al. Leflunomide does not alter the lipid profile in rheumatoid arthritis [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 155 Van Halm VP, Nurmohamed MT, van Schaardenburg D, et al. Leflunomide does not alter the lipid profile in rheumatoid arthritis [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 155
98.
Zurück zum Zitat Prokopowitsch AS, Diogenes AHM, Borgees CT, et al. Leflunomide induces progressive increase in rheumatoid arthritis lipid profile [abstract]. Arthritis Rheum 2002; 46 Suppl.: S164 Prokopowitsch AS, Diogenes AHM, Borgees CT, et al. Leflunomide induces progressive increase in rheumatoid arthritis lipid profile [abstract]. Arthritis Rheum 2002; 46 Suppl.: S164
101.
Zurück zum Zitat Hoechst Marion Roussel. Arava™ (leflunomide) prescribing information. Kansas City (MO): Hoechst Marion Roussel 1998 Hoechst Marion Roussel. Arava™ (leflunomide) prescribing information. Kansas City (MO): Hoechst Marion Roussel 1998
104.
Zurück zum Zitat Elliott M, Maini R, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factorα. Lancet 1994; 344: 1125–7PubMedCrossRef Elliott M, Maini R, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factorα. Lancet 1994; 344: 1125–7PubMedCrossRef
105.
Zurück zum Zitat Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341–59PubMedCrossRef Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341–59PubMedCrossRef
106.
Zurück zum Zitat Elliott MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factora (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10PubMedCrossRef Elliott MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factora (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10PubMedCrossRef
107.
Zurück zum Zitat Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factora monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1999; 41: 1552–63CrossRef Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factora monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1999; 41: 1552–63CrossRef
108.
Zurück zum Zitat Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9 Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9
109.
Zurück zum Zitat Smolen JS, Emery P, Bathon J, et al. Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: preliminary results of the ASPIRE trial [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 64CrossRef Smolen JS, Emery P, Bathon J, et al. Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: preliminary results of the ASPIRE trial [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 64CrossRef
111.
Zurück zum Zitat Hyrich KL, Silman AJ, Watson KD, et al. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004 Dec; 63(12): 1538–43PubMedCrossRef Hyrich KL, Silman AJ, Watson KD, et al. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004 Dec; 63(12): 1538–43PubMedCrossRef
112.
Zurück zum Zitat Neven N, Vis M, Voskuyl AE, et al. Safety of infliximab in daily practice in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 175 Neven N, Vis M, Voskuyl AE, et al. Safety of infliximab in daily practice in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 175
113.
Zurück zum Zitat Strand V, Keystone E. Anticytokine therapies in rheumatoid arthritis. In: Rose BD, editor. UpToDate. Wellesley (MA): UpToDate, 2003 Strand V, Keystone E. Anticytokine therapies in rheumatoid arthritis. In: Rose BD, editor. UpToDate. Wellesley (MA): UpToDate, 2003
114.
Zurück zum Zitat Francis GS. TNF-α and heart failure: the difference between proof of principle and hypothesis testing. Circulation 1999; 99: 3213–4PubMedCrossRef Francis GS. TNF-α and heart failure: the difference between proof of principle and hypothesis testing. Circulation 1999; 99: 3213–4PubMedCrossRef
115.
Zurück zum Zitat Chung ES, Packer M, Hung Lo K, et al. Randomized, double-blind placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure. Circulation 2003; 107: 3133–40PubMedCrossRef Chung ES, Packer M, Hung Lo K, et al. Randomized, double-blind placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure. Circulation 2003; 107: 3133–40PubMedCrossRef
116.
Zurück zum Zitat Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138(10): 807–11PubMed Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138(10): 807–11PubMed
118.
Zurück zum Zitat Choy EHS, Panyi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–16PubMedCrossRef Choy EHS, Panyi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–16PubMedCrossRef
119.
Zurück zum Zitat Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999; 56: 945–66CrossRef Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999; 56: 945–66CrossRef
120.
Zurück zum Zitat Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7PubMedCrossRef Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7PubMedCrossRef
121.
Zurück zum Zitat Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9PubMedCrossRef Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9PubMedCrossRef
122.
Zurück zum Zitat Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93PubMedCrossRef Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93PubMedCrossRef
123.
Zurück zum Zitat Spencer-Green G, Genovese M, Martin RW, et al. Enbrel® (etanercept) vs methotrexate (MTX) in early rheumatoid arthritis (ERA trial): two-year follow-up [abstract]. J Rheumatol 2001 Jul; 28 Suppl. 63: 106 Spencer-Green G, Genovese M, Martin RW, et al. Enbrel® (etanercept) vs methotrexate (MTX) in early rheumatoid arthritis (ERA trial): two-year follow-up [abstract]. J Rheumatol 2001 Jul; 28 Suppl. 63: 106
124.
Zurück zum Zitat Genovese M, Martin R, Fleischmann R, et al. Etanercept (Enbrel®) in early erosive rheumatoid arthritis (ERA trial): observations at 3 years [abstract]. Arthritis Rheum 2001 Sep; 44 Suppl. 9: 78 Genovese M, Martin R, Fleischmann R, et al. Etanercept (Enbrel®) in early erosive rheumatoid arthritis (ERA trial): observations at 3 years [abstract]. Arthritis Rheum 2001 Sep; 44 Suppl. 9: 78
125.
Zurück zum Zitat Genovese M, Martin R, Fleischmann R, et al. Etanercept (Enbrel®) in early erosive rheumatoid arthritis (ERA trial): 4-year clinical and radiographic data [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 183 Genovese M, Martin R, Fleischmann R, et al. Etanercept (Enbrel®) in early erosive rheumatoid arthritis (ERA trial): 4-year clinical and radiographic data [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 183
126.
Zurück zum Zitat Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Lancet 2004 Feb 28; 363(9410): 675–81 Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Lancet 2004 Feb 28; 363(9410): 675–81
127.
Zurück zum Zitat Fleischmann R, Iqbal I, Nandeswar P, et al. Safety and efficacy of disease-modifying antirheumatic drugs: focus on the benefits and risks of etanercept. Drug Saf 2002; 25: 173–97PubMedCrossRef Fleischmann R, Iqbal I, Nandeswar P, et al. Safety and efficacy of disease-modifying antirheumatic drugs: focus on the benefits and risks of etanercept. Drug Saf 2002; 25: 173–97PubMedCrossRef
128.
Zurück zum Zitat Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27(5): 307–24PubMedCrossRef Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27(5): 307–24PubMedCrossRef
129.
Zurück zum Zitat Keating GM, Jarvis B. Management of rheumatoid arthritis: defining the role of etanercept. Dis Manage Health Outcomes 2002; 10: 17–39CrossRef Keating GM, Jarvis B. Management of rheumatoid arthritis: defining the role of etanercept. Dis Manage Health Outcomes 2002; 10: 17–39CrossRef
131.
Zurück zum Zitat Machold KP, Smolen JS. Adalimumab: a new TNF-α antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther 2003; 3: 351–60PubMed Machold KP, Smolen JS. Adalimumab: a new TNF-α antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther 2003; 3: 351–60PubMed
133.
Zurück zum Zitat Weinblatt MW, Keystone EC, Furst DE, et al. Adalimumab, a fully human-antitumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003; 48: 35–45CrossRef Weinblatt MW, Keystone EC, Furst DE, et al. Adalimumab, a fully human-antitumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003; 48: 35–45CrossRef
134.
Zurück zum Zitat Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004 May; 50(5): 1400–11PubMedCrossRef Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004 May; 50(5): 1400–11PubMedCrossRef
135.
Zurück zum Zitat van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004 May; 63(5): 508–16PubMedCrossRef van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004 May; 63(5): 508–16PubMedCrossRef
136.
Zurück zum Zitat Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003 Dec; 30(12): 2563–71PubMed Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003 Dec; 30(12): 2563–71PubMed
137.
Zurück zum Zitat Arend WP, Welgus HG, Thopson RC, et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990; 85: 1694–7PubMedCrossRef Arend WP, Welgus HG, Thopson RC, et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990; 85: 1694–7PubMedCrossRef
141.
Zurück zum Zitat Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. 990145 Study Group. Ann Rheum Dis 2004 Sep; 63(9): 1062–8CrossRef Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. 990145 Study Group. Ann Rheum Dis 2004 Sep; 63(9): 1062–8CrossRef
142.
Zurück zum Zitat Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–204PubMedCrossRef Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–204PubMedCrossRef
143.
Zurück zum Zitat Fleischmann RM, Schlechtman J, Bennett R, et al. Anakinra a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1RA) in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 927–34PubMedCrossRef Fleischmann RM, Schlechtman J, Bennett R, et al. Anakinra a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1RA) in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 927–34PubMedCrossRef
144.
Zurück zum Zitat Schiff M, Bulpitt K, Weaver A, et al. Safety of combination therapy with Kineret™ (anakinra) and etanercept in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2001; 44 Suppl.: S79 Schiff M, Bulpitt K, Weaver A, et al. Safety of combination therapy with Kineret™ (anakinra) and etanercept in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2001; 44 Suppl.: S79
145.
Zurück zum Zitat Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology 2003; 42 Suppl. 2: ii29–35PubMedCrossRef Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology 2003; 42 Suppl. 2: ii29–35PubMedCrossRef
146.
Zurück zum Zitat The European Agency for the Evaluation of Medicinal Products. Post-authorisation evaluation of medicines for human use-EMEA Public Statement: increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept) [online]. Available from URL: http://www.emea.eu.int/pdfs/human/press/pus/3163102en.pdf [Accessed 2003 Oct 19] The European Agency for the Evaluation of Medicinal Products. Post-authorisation evaluation of medicines for human use-EMEA Public Statement: increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept) [online]. Available from URL: http://​www.​emea.​eu.​int/​pdfs/​human/​press/​pus/​3163102en.​pdf [Accessed 2003 Oct 19]
147.
Zurück zum Zitat Maetzel A, Strand V, Tugwell P, et al. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. Pharmacoeconomics 2002; 20(1): 61–70PubMedCrossRef Maetzel A, Strand V, Tugwell P, et al. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. Pharmacoeconomics 2002; 20(1): 61–70PubMedCrossRef
148.
Zurück zum Zitat Choi HK, Seeger JD, Kuntz KM. A costs-effectiveness analysis of treatment options for patients with methotrexate-naive rheumatoid arthritis. J Rheumatol 2002; 29: 1156–65PubMed Choi HK, Seeger JD, Kuntz KM. A costs-effectiveness analysis of treatment options for patients with methotrexate-naive rheumatoid arthritis. J Rheumatol 2002; 29: 1156–65PubMed
149.
Zurück zum Zitat Yazdani C, McLaughlin T, Cummins G, et al. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. Am J Manag Care 2001; 7 (13 Suppl.): S419–26PubMed Yazdani C, McLaughlin T, Cummins G, et al. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. Am J Manag Care 2001; 7 (13 Suppl.): S419–26PubMed
150.
Zurück zum Zitat Maetzel A, Strand V, Tugwell P, et al. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002; 47: 655–61PubMedCrossRef Maetzel A, Strand V, Tugwell P, et al. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002; 47: 655–61PubMedCrossRef
151.
Zurück zum Zitat Maetzel A, Bombardier C, Strand V, et al. How US and Canadian rheumatologists treat moderate or aggressive rheumatoid arthritis. J Rheumatol 1998; 25: 2331–8PubMed Maetzel A, Bombardier C, Strand V, et al. How US and Canadian rheumatologists treat moderate or aggressive rheumatoid arthritis. J Rheumatol 1998; 25: 2331–8PubMed
152.
Zurück zum Zitat Welsing PMJ, Severens JL, Hartman M, et al. Modelling study into cost-effectiveness over 5 year of treatment strategies including TNF-blocking treatment and leflunomide in the Netherlands [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 108CrossRef Welsing PMJ, Severens JL, Hartman M, et al. Modelling study into cost-effectiveness over 5 year of treatment strategies including TNF-blocking treatment and leflunomide in the Netherlands [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 108CrossRef
153.
Zurück zum Zitat Verhoeven AC, Bibo JC, Boers M, et al. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA trial group. Br J Rheumatol 1998; 37: 1102–9 Verhoeven AC, Bibo JC, Boers M, et al. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA trial group. Br J Rheumatol 1998; 37: 1102–9
154.
Zurück zum Zitat Korthals-de Bos IBC, van Tulder MW, Boers M, et al. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone. J Rheumatol 2004; 31: 1709–16PubMed Korthals-de Bos IBC, van Tulder MW, Boers M, et al. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone. J Rheumatol 2004; 31: 1709–16PubMed
155.
Zurück zum Zitat Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347–56PubMedCrossRef Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347–56PubMedCrossRef
156.
Zurück zum Zitat Choi HK, Seeger JD, Kuntz KM. A costs-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000; 43: 2316–27PubMedCrossRef Choi HK, Seeger JD, Kuntz KM. A costs-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000; 43: 2316–27PubMedCrossRef
157.
Zurück zum Zitat Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis: the Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137–41PubMedCrossRef Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis: the Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137–41PubMedCrossRef
158.
Zurück zum Zitat O’Dell JR, Haire C, Erikson N, et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol Suppl 1996; 44: 72–4 O’Dell JR, Haire C, Erikson N, et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol Suppl 1996; 44: 72–4
159.
Zurück zum Zitat Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478–86PubMed Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478–86PubMed
160.
Zurück zum Zitat Kavanaugh A, Heudebert G, Cush J, et al. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996; 25: 297–307PubMedCrossRef Kavanaugh A, Heudebert G, Cush J, et al. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996; 25: 297–307PubMedCrossRef
161.
Zurück zum Zitat Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209–18PubMedCrossRef Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209–18PubMedCrossRef
162.
Zurück zum Zitat Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347–56PubMedCrossRef Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347–56PubMedCrossRef
163.
Zurück zum Zitat Chiou CF, Wanke LA, Reyes C, et al. A cost-efficacy comparison of biologic agents in the treatment of rheumatoid arthritis [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 353CrossRef Chiou CF, Wanke LA, Reyes C, et al. A cost-efficacy comparison of biologic agents in the treatment of rheumatoid arthritis [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 353CrossRef
164.
Zurück zum Zitat Leardini G, Ganguly R, Singh A. Cost-effectiveness analysis of etanercept versus infliximab and anakinra in the treatment of rheumatoid arthritis in Italy [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S460CrossRef Leardini G, Ganguly R, Singh A. Cost-effectiveness analysis of etanercept versus infliximab and anakinra in the treatment of rheumatoid arthritis in Italy [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S460CrossRef
165.
Zurück zum Zitat Chiou CF, Wanke LA, Reyes C, et al. Comparison of the cost-efficacy in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S263 Chiou CF, Wanke LA, Reyes C, et al. Comparison of the cost-efficacy in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S263
166.
Zurück zum Zitat Singh A, Wanke LA, Malone DC, et al. Cost-efficacy comparison of adalimumab and etanercept in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S461CrossRef Singh A, Wanke LA, Malone DC, et al. Cost-efficacy comparison of adalimumab and etanercept in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S461CrossRef
167.
Zurück zum Zitat Bansback NJ, Brennan A, Sengupta N, et al. Cost effectiveness of adalimumab (Humira™) in the treatment of patients with moderate to severe rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S215 Bansback NJ, Brennan A, Sengupta N, et al. Cost effectiveness of adalimumab (Humira™) in the treatment of patients with moderate to severe rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S215
168.
Zurück zum Zitat Kobelt G, Jonsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003; 42: 326–35PubMedCrossRef Kobelt G, Jonsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003; 42: 326–35PubMedCrossRef
169.
Zurück zum Zitat Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002; 113: 400–8PubMedCrossRef Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002; 113: 400–8PubMedCrossRef
170.
Zurück zum Zitat Nuijten MJC, Engelfriet P, Duijn K, et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001; 19: 1051–64PubMedCrossRef Nuijten MJC, Engelfriet P, Duijn K, et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001; 19: 1051–64PubMedCrossRef
171.
Zurück zum Zitat Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results from a 5 year follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000 Jun; 39 (6): 603–11 Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results from a 5 year follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000 Jun; 39 (6): 603–11
172.
Zurück zum Zitat Lindkvist E, Saxne T, Geborek P, et al. Ten-year outcome in a cohort of early rheumatoid arthritis patients-health status, disease process and damage. Ann Rheum Dis 2002; 61: 1055–9CrossRef Lindkvist E, Saxne T, Geborek P, et al. Ten-year outcome in a cohort of early rheumatoid arthritis patients-health status, disease process and damage. Ann Rheum Dis 2002; 61: 1055–9CrossRef
173.
Zurück zum Zitat Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/ interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000; 108: 366–73PubMedCrossRef Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/ interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000; 108: 366–73PubMedCrossRef
174.
Zurück zum Zitat Geborek P, Crnkic M, Pterson IF, et al. South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793–8 Geborek P, Crnkic M, Pterson IF, et al. South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793–8
175.
Zurück zum Zitat Malone DC, Ortmeier BG. Cost effectiveness analysis of etanercept versus infliximab in the treatment of rheumatoid arthritis patients. Ann Rheum Dis 2003; 62 Suppl. 1: 353CrossRef Malone DC, Ortmeier BG. Cost effectiveness analysis of etanercept versus infliximab in the treatment of rheumatoid arthritis patients. Ann Rheum Dis 2003; 62 Suppl. 1: 353CrossRef
176.
Zurück zum Zitat Den Breeder AA, Creemers MCW, van Gestel AM, et al. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis in patients treated with TNFα. Rheumatology 2002; 41: 638–42CrossRef Den Breeder AA, Creemers MCW, van Gestel AM, et al. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis in patients treated with TNFα. Rheumatology 2002; 41: 638–42CrossRef
177.
Zurück zum Zitat Bresnihan B, Chan WW, Woolley DM. Productivity improvement in patients with rheumatoid arthritis receiving anakinra treatment [abstract]. Ann Rheum Dis 2002; 61 Suppl. 1: 182CrossRef Bresnihan B, Chan WW, Woolley DM. Productivity improvement in patients with rheumatoid arthritis receiving anakinra treatment [abstract]. Ann Rheum Dis 2002; 61 Suppl. 1: 182CrossRef
178.
Zurück zum Zitat Guh DP, Marra CA, Woolcott JC, et al. Cost-effectiveness of anakinra plus methotrexate verus methotrexate alone for the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S264 Guh DP, Marra CA, Woolcott JC, et al. Cost-effectiveness of anakinra plus methotrexate verus methotrexate alone for the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S264
179.
Zurück zum Zitat Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173–7PubMedCrossRef Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173–7PubMedCrossRef
180.
Zurück zum Zitat De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Breedveld FC, et al. Clinical and radiological outcomes after one-year follow-up of the BEST study, a randomized trial comparing four different strategies in early rheumatoid arthritis [abstract no. LB 18]. ACR/ ARHP 67th Annual Scientific Meeting; 2003 Oct 23–28; Orlando (FL) [online]. Available from URL: http://www.abstractsonline.com/viewer/searchAdvancedResults.asp [Accessed 2003 Oct 11] De Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Breedveld FC, et al. Clinical and radiological outcomes after one-year follow-up of the BEST study, a randomized trial comparing four different strategies in early rheumatoid arthritis [abstract no. LB 18]. ACR/ ARHP 67th Annual Scientific Meeting; 2003 Oct 23–28; Orlando (FL) [online]. Available from URL: http://​www.​abstractsonline.​com/​viewer/​searchAdvancedRe​sults.​asp [Accessed 2003 Oct 11]
181.
Zurück zum Zitat Cannon GW, Starnd V, Scarazzini L, et al. Comparison of adverse event reporting rates for etanercept, infliximab, leflunomide and methotrexate [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S242 Cannon GW, Starnd V, Scarazzini L, et al. Comparison of adverse event reporting rates for etanercept, infliximab, leflunomide and methotrexate [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S242
182.
Zurück zum Zitat Gabriel SE, Crowson CS, Luthra HS. Modeling lifetime costs of rheumatoid arthritis. J Rheumatol 1999; 26: 1269–74PubMed Gabriel SE, Crowson CS, Luthra HS. Modeling lifetime costs of rheumatoid arthritis. J Rheumatol 1999; 26: 1269–74PubMed
183.
Zurück zum Zitat Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease modifying antirheumatic drugs. Pharmacoeconomics 2001; 19: 715–28PubMedCrossRef Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease modifying antirheumatic drugs. Pharmacoeconomics 2001; 19: 715–28PubMedCrossRef
184.
Zurück zum Zitat Pressman Lovinger S. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost. JAMA 2003; 289: 3229–30PubMedCrossRef Pressman Lovinger S. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost. JAMA 2003; 289: 3229–30PubMedCrossRef
185.
Zurück zum Zitat Wolbink G, de Groot E, Lems W, et al. Relation between serum levels of infliximab, C-reactive protein and clinical response to infliximab in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S136 Wolbink G, de Groot E, Lems W, et al. Relation between serum levels of infliximab, C-reactive protein and clinical response to infliximab in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S136
186.
Zurück zum Zitat NIPO-rapport. Knelpunten bij de behandeling van reumatoide artritis. (B2460). Amsterdam: NIPO Amsterdam, 2002 Oct NIPO-rapport. Knelpunten bij de behandeling van reumatoide artritis. (B2460). Amsterdam: NIPO Amsterdam, 2002 Oct
187.
Zurück zum Zitat Brocq O, Plubel Y, Breuil V, et al. Etanercept: infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF alpha. Presse Med 2002; 31: 1836–9PubMed Brocq O, Plubel Y, Breuil V, et al. Etanercept: infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF alpha. Presse Med 2002; 31: 1836–9PubMed
188.
Zurück zum Zitat Buch MH, Bingham SJ, Bejarano V, et al. Do patients with rheumatoid arthritis demonstrate an improvement on etanercept following an inadequate response to infliximab [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S325CrossRef Buch MH, Bingham SJ, Bejarano V, et al. Do patients with rheumatoid arthritis demonstrate an improvement on etanercept following an inadequate response to infliximab [abstract]. Arthritis Rheum 2003; 48 (9 Suppl.): S325CrossRef
Metadaten
Titel
Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis
verfasst von
Dr Michael T. Nurmohamed
Ben A. C. Dijkmans
Publikationsdatum
01.04.2005
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 5/2005
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565050-00006

Weitere Artikel der Ausgabe 5/2005

Drugs 5/2005 Zur Ausgabe

Leading Article

Contraceptive Vaccines

Adis Drug Evaluation

Gatifloxacin